StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank:
Power Rank trend -> Rising
06/13/2025 16:00:00 EST
Indivior PLC Ordinary Shares (INDV)
Industry: Drug Manufacturers - Specialty & Generic
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, INDV has been trading in a range between $14.07 and $11.21 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
INDV is trading below resistance at $14.07, about 1% to the upside. There is support at $11.70 -16% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Indivior PLC Ordinary Shares $INDV entered a Green zone 35 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $14.6667, a potential upside of 5.59% from the recent price of 13.89. The stock is trading 22.25% (potential upside) below its 52 week high of $16.98 and 89.5 % (potential downside) above its 52 week low of $7.33 - based on the recent price.
Company Summary
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
News
| Indivior brings curtain down on turbulent 11-year run in London Indivior PLC (LSE:INDV) is set to end its secondary listing on the London Stock Exchange, drawing a line under a volatile 11-year chapter as a UK-listed company following its spin-out from Reckitt Benckiser in 2014. Its tenure as a London-listed company was marred by legal battles over its opioid treatments, loss of patent protection, investor distrust, and a growing disconnect between its UK listing and US-focused operations. Source: Proactive Investors Mon, 02 Jun 2025 04:15:58 -0400 Sentiment: Negative |
| Indivior to delist from London Stock Exchange, maintain Nasdaq listing Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. Source: Reuters Mon, 02 Jun 2025 02:33:59 -0400 Sentiment: Neutral |
| Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Source: PRNewsWire Mon, 02 Jun 2025 02:00:00 -0400 Sentiment: Neutral |
| Indivior Announces Patrick Barry as Chief Commercial Officer Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. Source: PRNewsWire Tue, 27 May 2025 08:30:00 -0400 Sentiment: Neutral |
| Indivior to Participate in Upcoming Investor Events RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4 th. Source: PRNewsWire Tue, 13 May 2025 10:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 16.975 52 Week Low: 7.33 Beta: 0.246 50 Day MA: 11.2666 200 Day MA: 10.6083 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.155 Qtr Revenue Growth YOY: -0.063 Forward PE: 0 Trailing PE: 0